These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 16611307)

  • 1. Circulating levels and clinical significance of soluble CD86 in myeloma patients.
    Hock BD; Drayson M; Patton WN; Taylor K; Kerr L; McKenzie JL
    Br J Haematol; 2006 Apr; 133(2):165-72. PubMed ID: 16611307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical significance of soluble CD86 levels in patients with acute myeloid leukemia and myelodysplastic syndrome.
    Hock BD; McKenzie JL; Patton WN; Haring LF; Yang Y; Shen Y; Estey EH; Albitar M
    Cancer; 2003 Oct; 98(8):1681-8. PubMed ID: 14534885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum syndecan-1, basic fibroblast growth factor and osteoprotegerin in myeloma patients at diagnosis and during the course of the disease.
    Kyrtsonis MC; Vassilakopoulos TP; Siakantaris MP; Kokoris SI; Gribabis DA; Dimopoulou MN; Angelopoulou MK; Pangalis GA
    Eur J Haematol; 2004 Apr; 72(4):252-8. PubMed ID: 15089762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating levels and clinical significance of soluble CD40 in patients with hematologic malignancies.
    Hock BD; McKenzie JL; Patton NW; Drayson M; Taylor K; Wakeman C; Kantarjian H; Giles F; Albitar M
    Cancer; 2006 May; 106(10):2148-57. PubMed ID: 16598754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum BAFF predicts prognosis better than APRIL in diffuse large B-cell lymphoma patients treated with rituximab plus CHOP chemotherapy.
    Kim SJ; Lee SJ; Choi IY; Park Y; Choi CW; Kim IS; Yu W; Hwang HS; Kim BS
    Eur J Haematol; 2008 Sep; 81(3):177-84. PubMed ID: 18510703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Therapy of multiple myeloma. Results of sequential treatment with melphalan-prednisolone and the M2 protocol].
    Steinke B; Busch FW; Stapelfeld S; Ostendorf P; Waller HD
    Dtsch Med Wochenschr; 1984 Jun; 109(26):1015-9. PubMed ID: 6547386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined chemotherapy with ABCM versus melphalan for treatment of myelomatosis. The Medical Research Council Working Party for Leukaemia in Adults.
    MacLennan IC; Chapman C; Dunn J; Kelly K
    Lancet; 1992 Jan; 339(8787):200-5. PubMed ID: 1346171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum EGFR and serum HER-2/neu are useful predictive and prognostic markers in metastatic breast cancer patients treated with metronomic chemotherapy.
    Sandri MT; Johansson HA; Zorzino L; Salvatici M; Passerini R; Maisonneuve P; Rocca A; Peruzzotti G; Colleoni M
    Cancer; 2007 Aug; 110(3):509-17. PubMed ID: 17559147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Levels of the soluble forms of CD80, CD86, and CD83 are elevated in the synovial fluid of rheumatoid arthritis patients.
    Hock BD; O'Donnell JL; Taylor K; Steinkasserer A; McKenzie JL; Rothwell AG; Summers KL
    Tissue Antigens; 2006 Jan; 67(1):57-60. PubMed ID: 16451202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression.
    Mateos MV; Hernández JM; Hernández MT; Gutiérrez NC; Palomera L; Fuertes M; Garcia-Sanchez P; Lahuerta JJ; de la Rubia J; Terol MJ; Sureda A; Bargay J; Ribas P; Alegre A; de Arriba F; Oriol A; Carrera D; García-Laraña J; García-Sanz R; Bladé J; Prósper F; Mateo G; Esseltine DL; van de Velde H; San Miguel JF
    Haematologica; 2008 Apr; 93(4):560-5. PubMed ID: 18322252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human plasma contains a soluble form of CD86 which is present at elevated levels in some leukaemia patients.
    Hock BD; Patton WN; Budhia S; Mannari D; Roberts P; McKenzie JL
    Leukemia; 2002 May; 16(5):865-73. PubMed ID: 11986949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abnormalities of chromosome 1p/q are highly associated with chromosome 13/13q deletions and are an adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma.
    Wu KL; Beverloo B; Lokhorst HM; Segeren CM; van der Holt B; Steijaert MM; Westveer PH; Poddighe PJ; Verhoef GE; Sonneveld P; ;
    Br J Haematol; 2007 Feb; 136(4):615-23. PubMed ID: 17223915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of age on survival after intensive therapy for multiple myeloma: a population-based study by the Nordic Myeloma Study Group.
    Lenhoff S; Hjorth M; Westin J; Brinch L; Bäckström B; Carlson K; Christiansen I; Dahl IM; Gimsing P; Hammerström J; Johnsen HE; Juliusson G; Linder O; Mellqvist UH; Nesthus I; Nielsen JL; Tangen JM; Turesson I;
    Br J Haematol; 2006 May; 133(4):389-96. PubMed ID: 16643445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evolution of soluble forms of CD86, CD95 and CD95L molecules in liver transplant recipients.
    Marín LA; Moya-Quiles MR; Miras M; Minguela A; Bermejo J; Ramírez P; García-Alonso AM; Parrilla P; Alvarez-López MR; Muro M
    Transpl Immunol; 2012 Mar; 26(2-3):94-100. PubMed ID: 22182632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic factors in limited-stage small cell lung cancer of patients treated with combined modality approach.
    Cetingöz R; Cetinayak HO; Sen RC; Demiral AN; Akkoçlu A; Osma E; Kargi A; Oztop I; Onen A; Kinay M;
    J BUON; 2006; 11(1):31-7. PubMed ID: 17318949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of carcinoembryonic antigen and CYFRA21-1 in patients with pathological stage I non-small cell lung cancer.
    Matsuoka K; Sumitomo S; Nakashima N; Nakajima D; Misaki N
    Eur J Cardiothorac Surg; 2007 Sep; 32(3):435-9. PubMed ID: 17611117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Prognosis and treatment strategies of primary B-cell and NK/T-cell nasopharyngeal non-Hodgkin's lymphoma at early stage].
    Zou GR; Zhang YJ; Xie FY; Zheng W; Li HX; Xia YF; Lin TY; Lu TX
    Ai Zheng; 2006 Dec; 25(12):1543-9. PubMed ID: 17166383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: comparative analysis of efficacy and toxicity.
    Jo JC; Kang BW; Jang G; Sym SJ; Lee SS; Koo JE; Kim JW; Kim S; Huh J; Suh C
    Ann Hematol; 2008 Jan; 87(1):43-8. PubMed ID: 17710401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble syndecan-1 level at diagnosis is an independent prognostic factor in multiple myeloma and the extent of fall from diagnosis to plateau predicts for overall survival.
    Lovell R; Dunn JA; Begum G; Barth NJ; Plant T; Moss PA; Drayson MT; Pratt G;
    Br J Haematol; 2005 Aug; 130(4):542-8. PubMed ID: 16098068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.